$Medicus Pharma (MDCX.US)$ The interim data analysis timeline and 50% enrollment milestone in Medicus Pharma's Phase 2 SKNJCT-003 trial represents a important inflection point for their novel BCC treatment. The previous Phase 1 results showing 6 complete responses with no serious adverse events provides a strong foundation for Phase 2 success, particularly noteworthy given the diverse patient profile and 100% response rate in nodular BCC cases. The trial design incorpor...
$Medicus Pharma (MDCX.US)$ Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region Monday, 2nd December at 7:30 am TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region . Under the agreemen...
Medicus Pharma Stock Forum
The interim data analysis timeline and 50% enrollment milestone in Medicus Pharma's Phase 2 SKNJCT-003 trial represents a important inflection point for their novel BCC treatment. The previous Phase 1 results showing 6 complete responses with no serious adverse events provides a strong foundation for Phase 2 success, particularly noteworthy given the diverse patient profile and 100% response rate in nodular BCC cases.
The trial design incorpor...
Skin Cancer Breakthrough: Medicus Phase 2 Trial Shows Promise After Phase 1 Success
📊⚡️📊
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Monday, 2nd December at 7:30 am
TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region
.
Under the agreemen...
📊⚡️📊
📊⚡️📊
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
No comment yet